Category: Uncategorized

Interview with Roumen Kofinov, MD, General Manager of BB-NCIPD Ltd (Bul Bio) & Özgür Tuncer, CEO & Executive Director Stablepharma Ltd I recently interviewed Mr Roumen Kofinov, MD, General Manager of BB-NCIPD Ltd (Bul Bio) & Özgür Tuncer, CEO & Executive Director Stablepharma Ltd. The two companies have entered into a partnership to produce the […]

UK-based biotech aims to be the first fridge-free vaccine company in the world. Stablepharma Ltd, a UK-based biotech who have a novel technology platform for fridge-free vaccines, has announced the completion of the first close of their Series A, with £2 million. Funding came from existing shareholders and new investors such as Ascension Ventures and […]

I recently interviewed Professor Alan Boyd, of Boyd Consultants, Fellow of the Academy of Medical Sciences and a member of the Stablepharma Ltd Advisory Board. We covered such topics as his work with the University of Oxford & AstraZenca on the COVID-19 programme, Boyds collaboration with Wellcome on a COVID-19 human infection study and Alan’s […]

The challenges related to keeping vaccines adequately cold in many parts of the world has highlighted the need to develop vaccines that are thermostable. In doing so, it would be possible to relieve key bottlenecks in the storage and supply of vaccines, enabling more patients access to the life-saving vaccines they require. Stablepharma has patented […]

Stablepharma has partnered with the University of Strathclyde to advance their COVID mRNA vaccine thermo-stabilisation technology following positive recent COVID mRNA stability data Bath, UK, 14 July 2021: A British breakthrough invention could form a crucial part in the urgent quest to combat Covid-19 and future virus pandemics. StablevaX™ allows vaccines to be transported and […]

Stablepharma are delighted to announce that Professor Saul Faust has accepted a position on Stablepharma’s Advisory Board. Professor Faust BMA, MBBS, FRCPCH, PhD, FHEA Professor or Paediatric Immunology and Infectious Diseases at the University of Southampton and Director of the NIHR Southampton Clinical Research Facility. He is currently leading the UK national 3rd dose COVID-19 […]

Having read the recent article by Peter Mwai, BBC Reality Check, ‘Covid-19 vaccines: Why some African states can’t use their vaccines’ really saddens and frustrates me as a scientist and I am sure, all of those involved in the creating, manufacturing and delivery of life saving vaccines feel the same. The World Health Organization reports […]

Express Pharma highlights the significant amount of H2020 funding that has helped UK Bio/Pharma companies advance their innovative technologies – Stablepharma Ltd received €50,000 to further develop its StablevaX™ technology. Full article can be found here.  Through the Brexit deal struck between the UK and EU on 24 December 2021, the UK will be part […]

As featured in Manufacturing Chemist publication 30th Mar 2021. https://www.manufacturingchemist.com/news/article_page/Stablepharma_and_BB-NCIPD_collaborating_on_thermally_stable_vaccine/175613 The companies are developing a version of BB-NCIPD’s Td vaccine using Stablepharma’s StablevaX technology Stablepharma has announced a collaboration with European vaccine manufacturer BB-NCIPD (Bul Bio), to develop a thermally stable version of the Tetanus diphtheria (Td) vaccine using the patented StablevaX formulation and device. […]

Excerpts of an article featured on Chemistry World publication, 19th January 2021; click here to read the full article. As the world celebrates the arrival of vaccines to protect against Covid-19, the logistics of distributing them is under the spotlight as never before. It’s a delicate balancing act – both heat and excessive cold damage […]